Furthermore, the potential of targeting the DR5 pathway is highlighted by a recent study demonstrating the potent efficacy of an anti-DR5 antibody–drug conjugate (Oba01), which delivers the cytotoxic agent monomethyl auristatin E (MMAE) to pancreatic cancer cells, inducing apoptosis and showing synergy with gemcitabine [56]. Here, TNFRSF10B is linked to pancreatic neoplasm.